Publicatie

Publicatie datum

Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024.

Maurel, M., Howard, J., Kissling, E., Pozo, F., Pérez-Gimeno, G., Buda, S., Sève, N., McKenna, A., Meijer, A., Rodrigues, A.P., Martínez-Baz, I., Mlinarić, I., Latorre-Margalef, N., Túri, G., Lazar, M., Mazagotos, C., Echeverria, A., Abela, S., Bourgeois, M., Machado, A., Dürrwald, R., Petrović, G., Oroszi, B., Jancoriene, L., Marin, A., Husa, P., Duffy, R., Dijkstra, F., Gallardo García, V., Goerlitz, L., Enouf, V., Bennett, C., Hooiveld, M., Guiomar, R., Trobago-Sanmartin, C., Višekruna Vučina, V., Samuelsson Hagey, T., Lameiras Azevedo, A.S., Castilla, J., Xuereb, G., Delaere, B., Gómez, V., Tolksdorf, K., Bacci, S., Nicolay, N., Kaczmarek, M., Mc Rose, A. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. Eurosurveillance: 2024, 29(8), p. e13243.

Lees online
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.